BioAtla Inc. (BCAB)
0.30
-0.03 (-7.92%)
At close: Mar 03, 2025, 3:59 PM
0.28
-6.67%
Pre-market: Mar 04, 2025, 06:47 AM EST
No 1D chart data available
| Bid | 0.28 |
| Market Cap | 17.58M |
| Revenue (ttm) | 15.25M |
| Net Income (ttm) | -98.22M |
| EPS (ttm) | -1.7 |
| PE Ratio (ttm) | -0.18 |
| Forward PE | -0.37 |
| Analyst | Hold |
| Ask | 0.33 |
| Volume | 514,852 |
| Avg. Volume (20D) | 1,084,041 |
| Open | 0.34 |
| Previous Close | 0.33 |
| Day's Range | 0.30 - 0.34 |
| 52-Week Range | 0.28 - 4.02 |
| Beta | 1.18 |
About BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, mel...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 65
Stock Exchange NASDAQ
Ticker Symbol BCAB
Website https://www.bioatla.com
Analyst Forecast
According to 2 analyst ratings, the average rating for BCAB stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 1550.17% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
2 months ago
-41.82%
BioAlta shares are trading lower after the company...
Unlock content with
Pro Subscription
3 months ago
-14.07%
BioAtla shares are trading lower. The stock may be reacting to the Scion Asset Management 13F filing disclosing an exit from their position in the company.
